{"id":"W2093783077","doi":"10.1158/1078-0432.ccr-06-2309","title":"Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma","year":2007,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":1075,"is_retracted":false,"has_abstract":true,"ca_institutions":"Immunovaccine (Canada)","funders":"National Institute of Neurological Disorders and Stroke; National Cancer Institute","keywords":"Medicine; Bevacizumab; Irinotecan; Glioma; Surgery; Internal medicine; Chemotherapy; Gastroenterology; Cancer; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002007415,0.001775,0.002408548,0.0004277331,0.0002839408,0.0007276651,0.0009599609,0.001037891,0.002217171],"category_scores_gemma":[0.001049699,0.0004899937,0.001009114,0.0003916401,0.0009320225,0.0004662508,0.0003807667,0.002816059,0.0005685412],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001170012,"about_ca_system_score_gemma":0.001961604,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001099402,"about_ca_topic_score_gemma":0.002101763,"domain_scores_codex":[0.9993165,0.000377643,0.00004488842,0.00008538186,0.00007318925,0.0001024787],"domain_scores_gemma":[0.9991166,0.0001094106,0.0002415825,0.00006226326,0.00005033661,0.0004197529],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7987017,0.04416473,0.008723975,0.0009424383,0.002016955,0.0006359356,0.0002933783,0.002296882,0.04322799,0.0002870135,0.003321887,0.09538712],"study_design_scores_gemma":[0.5835414,0.3994471,0.008043157,0.0000441513,0.0004577872,0.000644887,0.00004068164,0.001252796,0.004115153,0.0001228997,0.002269195,0.00002084398],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9931715,0.002582929,0.0004863111,0.0003389845,0.0001155082,0.002019958,0.0003086512,0.00007415645,0.0009020666],"genre_scores_gemma":[0.9888305,0.001613929,0.001996127,0.000686114,0.0002494371,0.003303884,0.001571985,0.00002139532,0.001726544],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002408548,"threshold_uncertainty_score":0.0106163,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2874148997796409,"score_gpt":0.5805459813262088,"score_spread":0.2931310815465679,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}